BACKGROUND AND PURPOSE: Reperfusion and recanalization have both been used as surrogate markers of clinical outcome in trials of stroke thrombolysis. We aimed to prove that the beneficial impact of recanalization with intravenous tissue plasminogen activator on clinical outcomes is attributable to reperfusion in the Echoplanar Imaging Thrombolytic Evaluation Trial (EPITHET). METHODS: EPITHET was a prospective, randomized, placebo-controlled trial of intravenous tissue plasminogen activator in the 3- to 6-hour window. Reperfusion was defined as >90% reduction in magnetic resonance perfusion-weighted imaging lesion volume and recanalization as improvement of MR angiographic Thrombolysis In Myocardial Infarction grading by > or =2 points from baseline to Day 3 to 5. RESULTS: At Day 3 to 5, reperfusion and recanalization with intravenous tissue plasminogen activator were strongly correlated. Reperfusion was associated with improved clinical outcome independent of whether recanalization occurred. In contrast, recanalization was not associated with clinical outcome when reperfusion was included as a covariate in regression analyses. CONCLUSIONS: Reperfusion is a surrogate marker of clinical outcomes independent of recanalization based on the criteria applied in EPITHET. The impact of recanalization on clinical outcomes was attributable to reperfusion.
RCT Entities:
BACKGROUND AND PURPOSE: Reperfusion and recanalization have both been used as surrogate markers of clinical outcome in trials of stroke thrombolysis. We aimed to prove that the beneficial impact of recanalization with intravenous tissue plasminogen activator on clinical outcomes is attributable to reperfusion in the Echoplanar Imaging Thrombolytic Evaluation Trial (EPITHET). METHODS: EPITHET was a prospective, randomized, placebo-controlled trial of intravenous tissue plasminogen activator in the 3- to 6-hour window. Reperfusion was defined as >90% reduction in magnetic resonance perfusion-weighted imaging lesion volume and recanalization as improvement of MR angiographic Thrombolysis In Myocardial Infarction grading by > or =2 points from baseline to Day 3 to 5. RESULTS: At Day 3 to 5, reperfusion and recanalization with intravenous tissue plasminogen activator were strongly correlated. Reperfusion was associated with improved clinical outcome independent of whether recanalization occurred. In contrast, recanalization was not associated with clinical outcome when reperfusion was included as a covariate in regression analyses. CONCLUSIONS: Reperfusion is a surrogate marker of clinical outcomes independent of recanalization based on the criteria applied in EPITHET. The impact of recanalization on clinical outcomes was attributable to reperfusion.
Authors: A D Horsch; J W Dankbaar; J M Niesten; T van Seeters; I C van der Schaaf; Y van der Graaf; W P Th M Mali; B K Velthuis Journal: AJNR Am J Neuroradiol Date: 2015-04-23 Impact factor: 3.825
Authors: T A Tomsick; P Khatri; T Jovin; B Demaerschalk; T Malisch; A Demchuk; M D Hill; E Jauch; J Spilker; J P Broderick Journal: Neurology Date: 2010-03-30 Impact factor: 9.910
Authors: F Dorn; A Kuntze-Soderqvist; S Popp; H Lockau; B Haller; C Zimmer; T Andersson; T Liebig Journal: Neuroradiology Date: 2011-10-21 Impact factor: 2.804
Authors: Hannah J Irvine; Ann-Christin Ostwaldt; Matthew B Bevers; Simone Dixon; Thomas Wk Battey; Bruce Cv Campbell; Stephen M Davis; Geoffrey A Donnan; Kevin N Sheth; Reza Jahan; Jeffrey L Saver; Chelsea S Kidwell; W Taylor Kimberly Journal: J Cereb Blood Flow Metab Date: 2017-07-21 Impact factor: 6.200
Authors: Mark W Parsons; Soren Christensen; Patrick McElduff; Christopher R Levi; Ken S Butcher; Deidre A De Silva; Martin Ebinger; P Alan Barber; Christopher Bladin; Geoffrey A Donnan; Stephen M Davis Journal: J Cereb Blood Flow Metab Date: 2010-01-20 Impact factor: 6.200
Authors: Olvert A Berkhemer; Shervin Kamalian; R Gilberto González; Charles B L M Majoie; Albert J Yoo Journal: Cardiovasc Eng Technol Date: 2013-12-01 Impact factor: 2.495